SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-20-309272
Filing Date
2020-12-03
Accepted
2020-12-03 12:31:01
Documents
13
Period of Report
2020-12-03
Items
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d67989d8k.htm   iXBRL 8-K 26025
2 EX-99.1 d67989dex991.htm EX-99.1 22553
  Complete submission text file 0001193125-20-309272.txt   180895

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA galt-20201203.xsd EX-101.SCH 3093
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE galt-20201203_lab.xml EX-101.LAB 18138
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE galt-20201203_pre.xml EX-101.PRE 11423
6 EXTRACTED XBRL INSTANCE DOCUMENT d67989d8k_htm.xml XML 3470
Mailing Address 4960 PEACHTREE INDUSTRIAL BOULEVARD SUITE 240 NORCROSS GA 30071
Business Address 4960 PEACHTREE INDUSTRIAL BOULEVARD SUITE 240 NORCROSS GA 30071 678-620-3186
GALECTIN THERAPEUTICS INC (Filer) CIK: 0001133416 (see all company filings)

IRS No.: 043562325 | State of Incorp.: NV | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-31791 | Film No.: 201366247
SIC: 2834 Pharmaceutical Preparations